LncRNA HOTTIP was essential for the antiviral effect of exosomes derived from macrophages treated with TAF. (A) The HBsAg level in the culture supernatants of HepAD38 cells successively treated with exosomes derived from the supernatants of THP-1-derived macrophages (MP) treated with TAF treatment (50 µmol/L) for 48 h Exo-MP(TAF) and then treated with PBS, siRNA negative control (siRNA-NC), or siRNA against lncRNA HOTTIP (siRNA-HOTTIP). (B) The HBeAg level in the culture supernatants of HepAD38 cells successively treated with Exo-MP(TAF) (10 μg/mL) and then treated with PBS, siRNA-NC, or siRNA-HOTTIP. (C) The HBV DNA level in the culture supernatants of HepAD38 cells successively treated with Exo-MP(TAF) (10 μg/mL) and then treated with PBS, siRNA-NC, or siRNA-HOTTIP. (D) The intracellular HBV cccDNA level in the culture supernatants of HepAD38 cells successively treated with Exo-MP(TAF) (10 μg/mL) and then treated with PBS, siRNA-NC, or siRNA-HOTTIP. (E) The HBsAg level in the culture supernatants of HepAD38 cells successively treated with Exo-MP(TAF) (10 μg/mL) and then treated with PBS, pcDNA3.1 vector negative control (pcDNA3.1-NC), or pcDNA3.1 vector carrying lncRNA HOTTIP (pcDNA3.1-HOTTIP). (F) The HBeAg level in the culture supernatants of HepAD38 cells successively treated with Exo-MP(TAF) (10 μg/mL) and then treated with PBS, pcDNA3.1-NC, or pcDNA3.1-HOTTIP. (G) The HBV DNA level in the culture supernatants of HepAD38 cells successively treated with Exo-MP(TAF) (10 μg/mL) and then treated with PBS, pcDNA3.1-NC, or pcDNA3.1-HOTTIP. (H) The intracellular HBV cccDNA level in the culture supernatants of HepAD38 cells successively treated with Exo-MP(TAF) (10 μg/mL) and then treated with PBS, pcDNA3.1-NC, or pcDNA3.1-HOTTIP. *p < 0.05, **p < 0.01, ***p < 0.001.